Engineered CXCL12 α locked dimer polypeptide

Details Engineered CXCL12 α locked dimer polypeptide Engineered CXCL12 α locked dimer polypeptide

2011-04-12

2011-04-12

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S198100, C424S185100, C435S069100, C530S350000

Reexamination Certificate

active

07923016

ABSTRACT:
The present invention provides a novel CXCL12-α2locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.

REFERENCES:
patent: 6875738 (2005-04-01), Clark-Lewis et al.
PCT/US2009/035318 International Search Report dated Jul. 14, 2009.
Veldkamp et al., “Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL 12)”, J. Mol. Biol., 2006; 359:1400-1409.
Veldkamp et al., “Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL 12”, Sci. Signal., 2008; 1:ra4.
Fernando et al., “Thermodynamic characterization of interleukin-8 monomer binding to CXCR1 receptor N-terminal domain”, FEBS J., 2007; 274:241-251.
Jin et al., “The human CC chemokine MIP-1beta dimer is not competent to bind to the CCR5 receptor”, J. Biol. Chem., 2007; 282:27976-27983.
Zlotnik et al., “Chemokines and cancer”, Int. J. Cancer, 2006; 119:2026-2029.
Rajarathnam et al., “Probing receptor binding activity of interleukin-8 dimer using a disulfide trap”, Biochemistry, 2006; 45:7882-7888.
Veldkamp et al., “The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin”, Protein Sci., 2005; 14:1071-1081.
Proudfoot et al., “Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines”, Proc. Natl. Acad. Sci. U.S.A., 2003; 100:1885-1890.
Muller et al, “Involvement of chemokine receptors in breast cancer metastasis”, Nature, 2001; 410:50-56.
Loetscher et al., “N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities”, J. Biol. Chem., 1998; 273:22279-22283.
Crump et al., “Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1”, EMBO J., 1997; 16:6996-7007.
Vianello et al., “Fugetaxis: active movement of leukocytes away from a chemokinetic agent”, J. Mol. Med., 2005; 83:752-763.

Affiliated with

Also associated with

Rating

Engineered CXCL12 α locked dimer polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Engineered CXCL12 α locked dimer polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineered CXCL12 α locked dimer polypeptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2699095